Clinical Trial Update: Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating the combination of Quizartinib and Omacetaxine Mepesuccinate for AML with FLT3-ITD mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Omacetaxine mepesuccinate (homoharringtonine)
• Quizartinib (Quizartinib)

Snippet

Sponsor: The University of Hong Kong | Conditions: AML, FLT3-ITD Mutation | Phase 2 | Status: UNKNOWN